On the heels of $225M royalty deal, Kodiak shoots for $250M raise to fund pivotal programs of its Eylea slayer
Baker Bros. didn’t have to wait long for Kodiak Sciences’ next stock raise, for which they pledged to invest $25 million. Just a day after nailing $225 million from a sale of future royalties to the investment firm, Kodiak is offering $250 million worth of shares $KOD on the public market.
Despite a slight drop pre-market, Kodiak’s current stock price, at $47, is still up 34% compared to Monday morning.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.